REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 15, 2023 at 04:22 am EDT
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 0.00006 million compared to KRW 0.00028 million a year ago. Net income was KRW 2,007.41 million compared to KRW 1,894.45 million a year ago.
Basic earnings per share from continuing operations was KRW 112 compared to KRW 100 a year ago. Diluted earnings per share from continuing operations was KRW 109 compared to KRW 82 a year ago. Basic earnings per share was KRW 112 compared to KRW 100 a year ago.
Diluted earnings per share was KRW 109 compared to KRW 82 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
